Citation:Tyrrell CJ, Altwein JE, Klippel F, Jurincic-Winkler C, Varenhorst E, Lunglmayr G, et al 2000
Tyrrell CJ, Altwein JE, Klippel F, Jurincic-Winkler C, Varenhorst E, Lunglmayr G, et al. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. Eur Urol 2000 Feb;37(2):205-11 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10705200.
Compare quality appraisals for each clinical question
- Is there any survival advantage for maximum androgen blockade (or combined hormone therapy) compared with single agent androgen blockade when used as first line therapy in metastatic disease?
- What should be done for patients with locally advanced disease who are not suitable candidates for surgery or radiotherapy – primary androgen deprivation at diagnosis or wait until clinical progression (localized or metastatic)?